...
首页> 外文期刊>American Journal of Transplantation >Liver Transplantation for Hepatitis C From Donation After Cardiac Death Donors: An Analysis of OPTN/UNOS Data
【24h】

Liver Transplantation for Hepatitis C From Donation After Cardiac Death Donors: An Analysis of OPTN/UNOS Data

机译:心脏死亡捐赠者捐赠后丙型肝炎的肝移植:OPTN / UNOS数据分析

获取原文
获取原文并翻译 | 示例
           

摘要

Donation after cardiac death (DCD) liver transplantation is increasing largely because of a shortage of organs. However, there are almost no data that have specifically assessed the impact of using DCD livers for HCV patients. We retrospectively studied adult primary DCD liver transplantation (630 HCV, 1164 non-HCV) and 54 129 donation after brain death (DBD) liver transplantation between 2002 and 2009 using the UNOS/OPTN database. With donation after brain death (DBD) livers, HCV recipients had significantly inferior graft survival compared to non-HCV recipients (p < 0.0001). Contrary to DBD donors, DCD livers used in HCV patients showed no difference in graft survival compared to non-HCV patients (p = 0.5170). Cox models showed DCD livers and HCV disease had poorer graft survival (HR = 1.80 and 1.28, p < 0.0001, respectively). However, the hazard ratio of DCD and HCV interaction was 0.80 (p = 0.02) and these results suggest that DCD livers on HCV disease do not fare worse than DCD livers on non-HCV disease. The graft survival of recent years (2006–2009) was significantly better than that in former years (2002–2005) (p = 0.0482). In conclusion, DCD liver transplantation for HCV disease showed satisfactory outcomes. DCD liver transplantation can be valuable option for HCV related end-stage liver disease.
机译:心脏死亡(DCD)肝移植后的捐赠在很大程度上由于器官短缺而增加。但是,几乎没有数据可以具体评估使用DCD肝脏对HCV患者的影响。我们使用UNOS / OPTN数据库回顾性研究了2002年至2009年之间成人原发DCD肝移植(630 HCV,1164非HCV)和脑死亡(DBD)肝移植后的54 129捐赠。与非HCV接受者相比,通过脑死亡(DBD)肝脏捐赠后,HCV接受者的移植存活率显着降低(p <0.0001)。与DBD供体相反,用于HCV患者的DCD肝脏与非HCV患者相比,移植物存活率无差异(p = 0.5170)。 Cox模型显示DCD肝脏和HCV疾病的移植物存活率较差(HR分别为1.80和1.28,p <0.0001)。但是,DCD和HCV相互作用的危险比为0.80(p = 0.02),这些结果表明,患有HCV疾病的DCD肝脏并没有比非HCV疾病的DCD肝脏更糟。近年来(2006-2009年)的移植物存活率明显优于往年(2002-2005年)(p = 0.0482)。总之,DCD肝移植治疗HCV疾病显示令人满意的结果。 DCD肝移植对于HCV相关的终末期肝病可能是有价值的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号